Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0O2WB
|
||||
Former ID |
DAP000809
|
||||
Drug Name |
Pyridostigmine
|
||||
Synonyms |
Pyridostigminum; Regonol; Pyridostigmine Bromine; Mestinon (TN); Mestinon-SR; Regonol (TN); AQ-776/42801589; Pyridinium, 3-hydroxy-1-methyl-, dimethylcarbamate (ester); Pyridinium, 3-(((dimethylamino)carbonyl)oxy)-1-methyl-(9CI); (1-methylpyridin-1-ium-3-yl) N,N-dimethylcarbamate; 1-methyl-3-pyridiniumyl dimethylcarbamate; 3-(((Dimethylamino)carbonyl)oxy)-1-methylpyridinium
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Myasthenia gravis [ICD9: 358; ICD10:G70.0] | Approved | [538182] | ||
Therapeutic Class |
Parasympathomimetics
|
||||
Company |
Valeant Pharmaceuticals
|
||||
Structure |
Download2D MOL |
||||
Formula |
C9H13N2O2+
|
||||
Canonical SMILES |
C[N+]1=CC=CC(=C1)OC(=O)N(C)C
|
||||
InChI |
1S/C9H13N2O2/c1-10(2)9(12)13-8-5-4-6-11(3)7-8/h4-7H,1-3H3/q+1
|
||||
InChIKey |
RVOLLAQWKVFTGE-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 155-97-5
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
9614, 866421, 4892591, 7437582, 7980440, 8153073, 11111694, 11335382, 11360621, 11364497, 11367059, 11369621, 11373077, 11377783, 11432882, 11461593, 11484637, 11488677, 11491724, 11495417, 15171335, 17153897, 29224064, 46506129, 47440132, 47662142, 47959602, 48334363, 50033601, 50100334, 50104217, 50361105, 90340824, 93166542, 95512043, 103310147, 103853547, 104147440, 104307965, 124750185, 124881247, 124881248, 124881249, 129188084, 134338090, 134974263, 137005304, 138967994, 140053019, 143458650
|
||||
SuperDrug ATC ID |
N07AA02
|
||||
SuperDrug CAS ID |
cas=000155975
|
||||
Target and Pathway | |||||
Target(s) | Acetylcholinesterase | Target Info | Inhibitor | [537124] | |
KEGG Pathway | Glycerophospholipid metabolism | ||||
Cholinergic synapse | |||||
Pathway Interaction Database | ATF-2 transcription factor network | ||||
PathWhiz Pathway | Phospholipid Biosynthesis | ||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.